IFNW1 Human, HEK

Interferon-Omega 1 is a single, glycosylated polypeptide chain consisting of 180 amino acids, with a molecular mass of 20.9 kDa . It is produced using recombinant DNA technology in HEK293 cells, which are human embryonic kidney cells . The recombinant form of IFNW1 is fused to a 6 amino acid His-Tag at the C-terminus and is purified using proprietary chromatographic techniques .

IFNW1 interacts with specific cell surface receptors, triggering a cascade of events that lead to the activation of various antiviral genes and immune modulatory pathways . This interaction primarily involves the Janus kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) signaling pathways . The activation of these pathways results in the transcription of interferon-stimulated genes (ISGs) that possess potent antiviral properties .

The biological activities of IFNW1 and its physiological role are still being investigated . However, it has been shown to bind to the alpha/beta receptor but not the interferon gamma receptor . This binding initiates a series of immune responses that help in combating viral infections .

Research on IFNW1 aims to understand its structural intricacies, signaling pathways, and broader implications in immune regulation and disease . Scientists are exploring its potential applications in therapeutic interventions, particularly in the treatment of viral infections such as hepatitis . The recombinant form of IFNW1 is used in laboratory research to study its effects and potential therapeutic benefits .

The recombinant IFNW1 solution is typically stored at 4°C if it will be used within 2-4 weeks. For longer storage periods, it is recommended to freeze the solution at -20°C with the addition of a carrier protein to avoid multiple freeze-thaw cycles . The solution is formulated with 10% glycerol and phosphate-buffered saline (pH 7.4) to maintain its stability .